MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • All Meetings
    • 2026 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Pharmacotherapy"

  • 2023 International Congress

    Sex differences in motor response to levodopa in early Parkinson’s disease

    M. Gevertzman, A. Hooyman, J. Longhurst, M. Landers (Las Vegas, USA)

    Objective: To evaluate differences between males and females in trajectory of motor response to levodopa in early Parkinson’s disease (PD). Background: Previous research has shown…
  • 2023 International Congress

    Can medicinal mushrooms help to stabilize or improve cognitive function in Parkinson’s patients with mild cognitive impairment?

    S. Elsas (Arlesheim, Switzerland)

    Objective: To explore whether the medicinal mushrooms Hericium erinaceus and Ganoderma lucidum may help to stabilize or improve cognitive function in Parkinson’s patients with mild…
  • 2023 International Congress

    Sex differences for off episodes in Parkinson’s disease

    A. Ratnavel, C. Jiang, A. Liu, K. Wang, A. Tsai, K. Wyman-Chick, E. Bayram (La Jolla, USA)

    Objective: To determine the sex differences for the frequency, duration, and impact of off episodes in Parkinson’s disease (PD). Background: Dopamine replacement therapy through oral…
  • 2023 International Congress

    Impaired Mitophagy and Mitochondrial-energetics in Parkinson’s disease: A Novel Therapeutic Strategy of Re-tasking Felodipine

    A. Roy, S. Choudhury, R. Banerjee, A. Costa, P. Sheshadri, M. Duchen, S. Dey, H. Kumar (Kolkata, India)

    Objective: This study aimed to validate impairment of mitochondrial energetics and mitophagy in PD and the action of felodipine in restoring altered Mitochondria-lysosome (Mito-Lyso) homeostasis.…
  • 2023 International Congress

    Correlation between dose of dopamine replacement therapy and King’s Parkinson’s Disease Pain Scale in Mexican Patients with Parkinson’s Disease

    A. Regalado Mustafá, D. Aguila Godinez, A. Herrera Ruiz, E. Santiago-de-La-Cruz, L. Lira Juárez, M. Medrano Delgado, M. Ruiz Mafud, A. Hernández-Medrano, D. Romero-Terán, M. Medina-Pérez, G. Cerda Hernández, M. Rodríguez-Violante, A. Cervantes-Arriaga, G. Hernandez Armesto, A. Abundes-Corona, A. Domínguez García, J. García Hernández, A. Alcocer Salas, K. Talavera Lagunas (Mexico City, Mexico)

    Objective: Investigate the relationship between the dose of dopamine replacement therapy (DRT) and pain severity as measured by the King's Parkinson's Disease Pain Scale (KPPS)…
  • 2023 International Congress

    The Comorbidity and Comedication Profiles of Patients with Progressive Supranuclear Palsy in Two German, Multicenter Cohorts: A Systematic Cross-Sectional Analysis

    S. Greten, F. Wegner, O. Krause, J. Heck, GU. Höglinger, M. Klietz (Hannover, Germany)

    Objective: To investigate the pattern of comorbidities and comedications in PSP patients compared to age-matched controls. Background: Although progressive supranuclear palsy (PSP) is usually diagnosed…
  • 2023 International Congress

    The role of genetic factors in the occurrence of levodopa-induced motor complications in Parkinson’s disease

    B. Radojević, N. Dragašević-Mišković, A. Milovanović, I. Petrović, M. Svetel, I. Jančić, D. Stanisavljević, O. Milićević, M. Savić, V. Kostić (Belgrade, Serbia)

    Objective: We aimed to evaluate the association of selected polymorphisms of COMT, DRD2, ANKK1, and DAT genes and the occurrence of levodopa-induced motor complications in…
  • 2023 International Congress

    How to dose extended-release carbidopa-levodopa capsules (IPX203) in Parkinson’s disease patients: Experience from the Phase 3 clinical trial

    R. Hauser, G. Banisadr, S. Fisher, H. Visser, R. D'Souza (Tampa, USA)

    Objective: To provide guidance on dosing of IPX203 based on clinical trial experience. Background: IPX203 is an extended-release, oral carbidopa-levodopa (CD-LD) formulation designed to rapidly…
  • 2023 International Congress

    Comparative efficacy of pharmacological cognitive treatments in Parkinson’s disease and Dementia of Lewy Bodies: systemic review & network meta-analysis

    F. Al Hajraf, S. Manohar, M. Hu (Oxford, United Kingdom)

    Objective: The aim of this study is to evaluate, compare and rank the currently available pharmacological cognitive treatments. Background: Treating cognitive impairment in Parkinson’s disease…
  • 2023 International Congress

    Changes in artistic style and Parkinson’s Disease

    AM. Diezma Martín, G. Tabar Comellas, MI. Morales-Casado, DD. Garcia Melendez, JW. Ruiz Gómez, P. Quintana Castro, M. Ennazeh Elkhaili, D. Rivero Rodríguez, N. López Ariztegui (Toledo, Spain)

    Objective: We present a Parkinson’s disease (PD) patient in whom dopamine agonists produced a dramatic change in her art style and production, and the subsequent…
  • « Previous Page
  • 1
  • …
  • 7
  • 8
  • 9
  • 10
  • 11
  • …
  • 36
  • Next Page »

Related Sites

International Parkinson and Movement Disorder Society

The Society that manages the annual International Congress »

International Congress

The official website for the International Congress of Parkinson’s and Movement Disorders® »

  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2026 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley